In addition, sunitinib as tyrosine kinase inhibitor might not be able to work efficiently to inhibit HER2/neu which involved in the tyrosine kinase mediated regulation of mammary gland since HER2/neu does not well express in NMU-induced breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.